goodness me, my buy in at the lucky 1 cent above IPO has been...

goodness me, my buy in at the lucky 1 cent above IPO has been bumpered with a double up at 87 cents; 87 CENTS... are you kidding me???? Here is my logic...

I know the EUA as been scuttled for CoviDx, but the normal FDA approval should happen... when? But surely a delay of, guessing, 6 months does not make the company invalid; and, to be honest, the product I am keen on is the FebriDx; so Lumos has a world wide market already for FebriDx

So by my thinking, the company is the same company it was at IPO (where people lined up at $1.25)... it is just delayed with one product line in one country (USA); if that unfortunate event allows me to top up at 87 cents, I will not complain

...and looking at FY21 presentation, the products sales (not services) is only about 11% of the company revenue; so there has been a delay in the hoped growth (CovidDx) which is PART of the 11% of revenue (and not even a major part); should that equate to a 30% share price drop... I dont think so; so either the IPO price was WAYYYYYYYYYYYY too HIGH or the current price is WAYYYYYYYYYYYYYYYYY too LOW. Time will tell.